1. Ramp-Aware Catalyst & Financial Arithmetic

Cupid Limited reported TTM revenue of ₹452 Cr and TTM PAT of ₹137 Cr (TTM EPS ₹2.72). At the current share price of ₹258.2, the company commands a market capitalization of ₹13,003 Cr, translating to a trailing P/E of 94.9x.

At its 33rd AGM on 2026-09-22, the company reiterated its upgraded FY27 guidance of ₹725–750 Cr revenue and ₹210–225 Cr PAT, while outlining multi-year ambitions of ₹1,085 Cr (FY28) and ₹1,500 Cr (FY29). The Palava facility (170,000 sq. ft.) is slated for commercialization in Q3 FY27.

• Year-1 Ramp (FY27 Guidance): The midpoint revenue guidance of ₹737.5 Cr implies a +63.2% uplift over TTM revenue (₹452 Cr). With Q1 FY27 delivering ₹154.7 Cr, achieving ₹737.5 Cr requires an average of ~₹194 Cr/quarter over the remaining three quarters, which aligns with Palava's commissioning.
• Steady-State Ramp (FY29 Target): Reaching ₹1,500 Cr by FY29 implies an annualized CAGR of ~35% from FY27. Assuming an operating margin normalization from current highs (35.5%) down to a sustainable 28.0% as personal care FMCG B2C scale expands, and an effective tax rate of 25%, FY29 PAT would reach ~₹315–400 Cr (steady-state PAT uplift of ~192% vs TTM).

2. Valuation & 'Already Priced In' Reality Check

A critical check of exchange disclosures reveals that Cupid already announced this exact FY27 guidance (₹725-750 Cr revenue / ₹210-225 Cr PAT) on 2026-08-07 alongside its Q1 FY27 results. The South Africa joint venture was disclosed on 2026-08-28, and the $5M GII Healthcare investment on 2026-07-29. Today's AGM release offers zero incremental financial catalysts; it is an executive reaffirmation.

More critically, the stock has already surged 492.5% in the trailing 12 months and 220.5% in 6 months. At 94.9x trailing P/E and ~60x FY27E guidance PAT (₹217.5 Cr), the near-term execution is aggressively front-loaded into the current valuation.

3. Industry Dynamics & Capital Allocation Concerns

While personal care and sexual wellness boast secular double-digit tailwinds (~12% industry CAGR) and Cupid holds an enviable moat via WHO/UNFPA female condom pre-qualifications, management is aggressively pivoting capital into non-core domains: 1. Baazar Style Retail Commitment: Committing ₹331.53 Cr to a value retail chain constitutes 73.7% of Cupid's entire Net Worth (₹450 Cr). This represents an enormous capital diversion away from core regulated manufacturing into working-capital-heavy retail distribution. 2. Auditor Change: A change in statutory auditors was reported on 2026-08-07. Combined with massive capital deployments into external retail vehicles, governance caution must be exercised.

4. Valuation Scenarios (24–36 Month Horizon)

• Bull Case (+75%): Cupid delivers ₹1,500 Cr in FY29 with best-in-class execution, maintaining a 28% PAT margin (₹420 Cr PAT). The market awards a sustained scarcity multiple of 55x P/E, driving market capitalization to ₹23,100 Cr (₹459/share).
• Base Case (+15%): Palava ramps smoothly, delivering FY27 PAT of ₹215 Cr and FY28 PAT of ₹280 Cr. FMCG scale-up dilutes margins slightly. As hyper-growth matures, the forward multiple derates from 60x to 45x FY28 PAT, yielding a market cap of ₹12,600–15,000 Cr (₹250–298/share).
• Bear Case (-55%): Retail venture into Baazar Style generates asset write-downs or extended receivables; Palava capacity takes longer to absorb. PAT plateaus at ₹160 Cr. Valuation violently de-rates toward peer group median (peer median P/E is 26.6x) to 35x P/E, causing market capitalization to sink to ₹5,600 Cr (₹111/share).

5. Verdict Rationale

Cupid is a phenomenal operational turnaround with 33% ROCE and exceptional quarterly growth. However, for a stock standing at ₹13,003 Cr market cap and 95x trailing P/E, generating a true multibagger return (2x–3x) requires reaching a ₹26,000–39,000 Cr valuation—which would demand an unsustainable 65–95x multiple on aspirational FY29 earnings. With the announcement already public for 6 weeks and significant capital tied up in third-party retail commitments, Cupid is rated UNLIKELY to deliver multibagger gains from this price point.

Cupid Limited (CUPID) - Investment Analysis & Multibagger Evaluation

Analysis Date: August 7, 2026 | Current Price: ₹262.1 | Market Cap: ₹9,583 Cr

1. Executive Summary & Announcement Assessment

Cupid Limited has delivered strong operational performance for Q1 FY27, reporting standalone revenue of ₹154.72 Cr (+158.7% YoY) and Net Profit of ₹44.16 Cr (+194.1% YoY). In addition, the Board granted in-principle approval for a greenfield manufacturing facility in West Bengal for medical devices and confirmed a strategic warrant investment in Baazar Style Retail.

While the financial results reflect operational growth, the top-line performance was already largely pre-announced/guided on June 30, 2026, when management revised FY27 revenue guidance upward to ₹660+ Cr and targeted Q1 revenue above ₹150 Cr. Thus, the fundamental catalyst is priced in near-term, though it validates execution capabilities.

2. Ramp-Aware Financial Impact & Growth Math

• FY26 Baseline: Revenue ₹357.3 Cr, Net Profit ₹107.8 Cr (EPS ₹2.95).
• Q1 FY27 Actuals: Revenue ₹154.72 Cr, Net Profit ₹44.16 Cr (Q1 standalone EPS ~₹1.21).
• Updated TTM Financials (Q2 FY26 - Q1 FY27):
• TTM Revenue = ₹84.0 + ₹93.5 + ₹120.0 + ₹154.7 = ₹452.2 Cr.
• TTM PAT = ₹24.0 + ₹32.8 + ₹36.0 + ₹44.2 = ₹137.0 Cr.
• TTM EPS = ~₹3.75 (on ~36.56 Cr shares).
• FY27 Target Run-Rate: Guidance of ₹660 Cr revenue at ~27-28% NPM yields an estimated FY27 PAT of ₹180–185 Cr (Forward EPS ~₹5.00).
• Execution Ramping: Palava facility 1.5x capacity expansion and newly approved West Bengal project will support revenue scale toward ₹1,000 Cr+ over FY28–FY29.

3. Industry Profile & Quality Gate

• Capital Intensity: Low to Medium. FMCG/Medical device manufacturing requires moderate machinery capex but high distribution investment.
• Execution Difficulty: Moderate. Reaching mass-market FMCG distribution across rural/urban India and acquiring CE/WHO international clearances involve multi-quarter ramp-up periods.
• Structural CAGR: ~12–15% for domestic sexual wellness, personal care FMCG, and IVD diagnostics.
• Quality Gate Assessment: PASSED. ROCE stands at 33.0%, D/E at 0.12, and OPM at 32.7%. High capital efficiency combined with regulatory moats (WHO/UNFPA prequalification) justifies a Grade A fundamental score.

4. Valuation Context & Risk-Reward Scenarios

At ₹262.1, Cupid trades at an explicit trailing P/E of 88.9x (or ~70.0x on newly updated TTM PAT of ₹137 Cr) and a P/B of 21.3x, compared to the peer median P/E of 30.5x. The stock has appreciated 680% over the past 12 months, reflecting market pricing of its transition from B2B vendor to B2C FMCG player.

Scenarios (24–36 Month Horizon):

1. Base Case (+35% upside to ~₹354): * Revenue reaches ₹1,000 Cr in FY28 with 25% NPM (PAT = ₹250 Cr; EPS = ₹6.84). * Valuation multiple compresses from ~89x to a sustainable growth multiple of ~52x P/E.
2. Bull Case (+85% upside to ~₹485): * Greenfield West Bengal site and B2C retail expansion push FY28 revenue to ₹1,250 Cr at 28% NPM (PAT = ₹350 Cr; EPS = ₹9.57). * Market maintains a premium P/E of 50–52x due to sustained 40%+ revenue growth.
3. Bear Case (-35% downside to ~₹170): * Margin compression due to raw material costs (latex/silicone) or execution delays drops NPM to 20% on ₹750 Cr revenue (PAT = ₹150 Cr; EPS = ₹4.10). * Multiple derates aggressively toward peer average of 35x P/E.

5. Multibagger Verdict Rationale

• Verdict: POSSIBLE (Score: 62/100).
• Rationale: Cupid exhibits strong operational momentum, high ROCE (33%), low leverage, and promoter alignment. However, after a 680% price surge in 12 months, trailing P/E of 88.9x and P/B of 21.3x mean substantial growth through FY27 is already embedded in the stock price. It remains a quality growth compounder, but further multi-fold upside from current levels requires execution beyond FY27 targets and successful assimilation of non-core investments.

1. Ramp-Aware Impact Math

• TTM Baseline: Revenue of ₹357 Cr, PAT of ₹108 Cr, and TTM EPS of ₹2.95.
• FY27 Guidance: Revised upward to ₹660+ Cr (an 85% increase over TTM revenue). This is supported by the operationalization of the Palava facility in Q2 FY27 and the PFSCM supply agreement.
• Q1 FY27 Target: Projected at ₹150 Cr+, which exceeds the previous record quarter of ₹120 Cr (Mar 2026) and represents 150% YoY growth over Q1 FY26 (₹59.8 Cr).
• Margin & PAT Projection: Assuming a conservative OPM of 32.0% (slightly below TTM 32.7% to account for raw material inflation) and a PAT margin of 28.0%, FY27 PAT is projected at ₹184.8 Cr.
• EPS Impact: With an estimated share count of 36.54 Cr shares, the forward EPS for FY27 is projected at ₹5.06, representing a 71.5% increase over TTM EPS of ₹2.95.

2. Industry Capital-Intensity & Expected CAGR

• Capital Intensity: Medium. The company is expanding capacity via the Palava facility, which requires upfront capex but scales rapidly once operational.
• Expected Industry CAGR: 15.0%. The sexual wellness and personal care industry in India is structurally growing due to low domestic condom penetration (<5%) and rising preventive healthcare awareness.

3. Multibagger Quality

• Growth & Acceleration: Revenue growth has accelerated from 53.3% YoY in Jun 2025 to 112.5% YoY in Mar 2026. PAT has followed a similar trajectory.
• Financial Health: ROCE is excellent at 33.0%, and the balance sheet is clean with a D/E ratio of 0.12 (Debt of ₹56 Cr vs Net Worth of ₹450 Cr).
• Promoter Holding: Stable at 46.0%, with no major pledges or governance red flags.

4. Scenario Analysis (12-24 Months)

• Base Case (35% Upside): Target price of ₹257. Assumes FY27 revenue of ₹660 Cr, PAT of ₹185 Cr, EPS of ₹5.06, and a P/E multiple of 50x (justified by 85% growth and high ROCE).
• Bull Case (75% Upside): Target price of ₹334. Assumes FY27 revenue of ₹700 Cr, PAT of ₹203 Cr, EPS of ₹5.56, and a P/E multiple of 60x due to sustained market leadership and margin expansion.
• Bear Case (-35% Downside): Target price of ₹124. Assumes execution delays at the Palava facility, revenue of ₹500 Cr, PAT margin drops to 24% (PAT of ₹120 Cr), EPS of ₹3.28, and P/E de-rates to 38x.

5. Verdict Rationale

Cupid is a high-quality business with a strong moat (WHO/UNFPA prequalification) and massive capacity expansion coming online. The upward revision of FY27 guidance is a strong positive catalyst. However, the stock has already run up 787% in the last 12 months, meaning a significant portion of the growth is already priced in. Therefore, it is classified as a 'POSSIBLE' multibagger rather than 'STRONG_CANDIDATE' due to high starting valuation and momentum risk, though the underlying fundamentals remain top-tier.

1. Ramp-Aware Impact Math

• Current State: Cupid's TTM revenue stands at ’247 Cr with a TTM PAT of ’62 Cr and TTM EPS of ’2.30. Operating profit margin (OPM) is strong at 28.1%.
• FY26 Guidance & Beat: Management has guided for ’335 Cr in revenue and ’100 Cr in PAT for FY26, and now expects to exceed this. Assuming a conservative beat of ’350 Cr in revenue and ’105 Cr in PAT:
• Year-1 (FY26) Revenue Uplift: Going from ’247 Cr TTM to ’350 Cr represents a 41.7% increase in revenue over the next 12 months.
• Year-1 (FY26) PAT Uplift: Going from ’62 Cr TTM to ’105 Cr represents a 69.4% increase in PAT.
• EPS Impact: With ~26.75 Cr outstanding shares, the forward FY26 EPS is projected to reach ’3.92 (up 70.4% from ’2.30 TTM).
• Steady-State (FY27-28) Projections: The Palava facility expansion (adding 770m male and 75m female condom capacity) and the Saudi Arabia FMCG facility (targeted for March 2027) will more than double current capacities. At full utilization by FY28, steady-state revenue is modeled at ’500 Cr (a 102.4% uplift over TTM) with PAT reaching ’150 Cr (EPS of ’5.60).

2. Industry Capital-Intensity & Expected CAGR

• Capital Intensity: Medium. While capacity expansions require upfront capex, the asset-turnover ratio in sexual wellness manufacturing is high, and the company maintains a very low debt-to-equity ratio of 0.06.
• Industry CAGR: The Indian sexual wellness and personal care market is structurally growing at an estimated 12-15% CAGR, driven by low domestic condom penetration (<5%) and rising preventive healthcare awareness. Cupid is significantly outperforming the industry growth rate due to market share gains and export expansions.

3. Multibagger Quality Assessment

• Growth & Acceleration: Quarterly revenue has accelerated sequentially from ’46.4 Cr (Dec 2024) to ’84.0 Cr (Sep 2025). Net profit has grown from ’11.0 Cr to ’24.0 Cr over the same period, showing clear operating leverage.
• Margins & ROCE: OPM is highly resilient at 28.1%, and ROCE stands at a healthy 17.0%, which is expected to expand as new capacities ramp up.
• Promoter & Debt: Promoter holding has increased from 42.51% to 45.56% in recent quarters, indicating strong insider alignment. Debt is negligible at ’19 Cr.

4. Scenario Analysis & Valuation

• Base Case: Exceeds FY26 guidance to hit ’350 Cr revenue and ’105 Cr PAT. FY27 revenue reaches ’450 Cr with Palava capacity online. Applying a forward P/E of 38x (justified by >50% earnings growth) on FY27 EPS of ’5.00 yields a target price of ’150 (78% upside).
• Bull Case: Rapid ramp-up of Palava and Saudi facilities. B2C FMCG scales to ’150 Cr. FY27 PAT reaches ’160 Cr (EPS of ’6.00). Applying a premium P/E of 35x yields a target price of ’210 (150% upside).
• Bear Case: Raw material inflation (latex/silicon oil) compresses margins to 22%. Delays in Saudi facility execution. FY27 PAT stagnates at ’90 Cr (EPS of ’3.36). P/E de-rates to 20x, yielding a target price of ’68 (-19% downside).

5. Verdict Rationale

Cupid is a high-margin, low-debt business with a unique global regulatory moat (WHO/UNFPA prequalification). Despite a massive 454% run-up over the past 12 months, the forward valuation remains highly attractive (forward P/E of ~21.4x on FY26 guided earnings) because the underlying earnings growth is accelerating. The combination of promoter buying, massive capacity doubling, and international expansion makes it a Strong Candidate for continued multibagger performance.

1. Ramp-Aware Impact Math

Cupid Limited has announced an in-principle board approval to set up its first international FMCG manufacturing facility in Saudi Arabia (KSA). Since this is a greenfield expansion with no immediate order book or specified deal value, the near-term revenue impact is zero.

• Year 1 (FY27): 0% revenue uplift. This period will be dominated by land acquisition, construction, and regulatory approvals.
• Steady-State (FY29 - 36 months out): Assuming a conservative capex of ₹40-50 Cr funded via internal accruals, a standard asset turnover of 1.5x yields ~₹60-75 Cr in peak revenue. Compared to the TTM revenue of ₹247 Cr, this represents a steady-state revenue uplift of ~25%.
• Margin & EPS Impact: FMCG operations in the GCC region typically command gross margins of 50%+, but high initial marketing and distribution costs will likely keep operating profit margins (OPM) around 20-22% (lower than Cupid's current high-margin condom business at 28.1%). At a 22% OPM, ₹60 Cr of incremental revenue yields ~₹13.2 Cr of EBITDA. Assuming standard depreciation and taxes, this translates to ~₹8-9 Cr in incremental PAT, representing an EPS uplift of ~15-20% on the expanded base.

2. Industry Capital-Intensity & Expected CAGR

The personal care and sexual wellness FMCG industry has medium capital intensity. While manufacturing setups are moderately capital-intensive, brand building, marketing, and distribution channel creation require substantial working capital and operational expenditure. The GCC personal care market is expected to grow at a structural CAGR of 8-10%, while India's domestic sexual wellness and premium personal care market is growing at 12-15% CAGR due to low penetration levels (<5% for condoms).

3. Multibagger Quality Assessment

• Financial Performance: Cupid is showing exceptional earnings acceleration. Quarterly revenue grew from ₹42 Cr (Sep 2024) to ₹84 Cr (Sep 2025), while PAT surged from ₹10 Cr to ₹24 Cr over the same period.
• Operating Metrics: OPM is robust at 28.1%, and ROCE stands at a healthy 17.0%. Debt is negligible at ₹19 Cr (D/E of 0.06).
• Promoter & Governance: Promoter holding is acceptable at 45.6%. The recent reduction in pledged shares from 36.13% to 20% is a major positive catalyst for corporate governance, though the remaining 20% pledge keeps risk elevated.

4. Valuation & Scenarios

Cupid trades at a trailing P/E of 42.3x, which is at a premium to the peer median of 30.5x. This premium is justified by its unique WHO/UNFPA pre-qualification moat in female condoms and its rapid earnings acceleration. * Bull Case (90% Upside): Successful execution of the Saudi plant ahead of schedule, rapid B2C FMCG scale-up in India to ₹125 Cr by FY26, and further reduction of promoter pledge to 0%. P/E re-rates to 50x on forward earnings. * Base Case (45% Upside): Saudi plant is commissioned in 24 months with moderate initial capacity utilization. Domestic capacity expansions drive steady 30% EPS growth. P/E stabilizes around 35-40x. * Bear Case (-25% Downside): Execution delays in KSA, high marketing cash burn in the GCC region yielding poor market share, and raw material inflation (latex/silicon oil) compressing margins back to <20%.

5. Verdict Rationale

Cupid is a high-growth business with a strong balance sheet and an expanding domestic moat. The Saudi expansion is a bold, long-term strategic move that diversifies the geographic and product mix. However, because it is a greenfield project with a long gestation period (24-36 months) and zero immediate revenue contribution, the near-term impact is limited. Combined with the remaining 20% promoter pledge, the verdict is capped at 'POSSIBLE' with a multibagger score of 68.